Biogen Idec (BIIB)

Add to Watchlists Create an Alert
230.62 -2.00  -0.86%   NASDAQ May 24, 9:42AM BATS Real time Currency in USD

Biogen Idec R&D Expense Quarterly:

284.34M for March 31, 2013
View Full Chart

Biogen Idec R&D Expense Quarterly Chart

    Biogen Idec Historical R&D Expense Quarterly Data

    Pro Data Export
    Dates:  to
    Viewing 1 of 1   First  Previous First    Next  Last   Last

    There is no data for the selected date range.

    Data for this Date Range  
    March 31, 2013 284.34M
    Dec. 31, 2012 345.18M
    Sept. 30, 2012 304.22M
    June 30, 2012 329.56M
    March 31, 2012 355.96M
    Dec. 31, 2011 338.93M
    Sept. 30, 2011 301.39M
    June 30, 2011 285.64M
    March 31, 2011 293.63M
    Dec. 31, 2010 45.87M
    Sept. 30, 2010 524.05M
       
    June 30, 2010 331.68M
    March 31, 2010 347.01M
    Dec. 31, 2009 283.08M
    Sept. 30, 2009 304.06M
    June 30, 2009 416.45M
    March 31, 2009 279.48M
    Dec. 31, 2008 292.77M
    Sept. 30, 2008 268.80M
    June 30, 2008 252.26M
    March 31, 2008 Go Pro

    About R&D Expense

    R&D expenses are a line item from many companies' income statements.

    R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.

    Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.

    An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
    Learn More

    Get data for

    BIIB R&D Expense Quarterly Benchmarks

    Companies
    Elan 31.90M
    Novartis 2.297B
    Celgene Corporation 452.40M

    BIIB R&D Expense Quarterly Rankings

    Overall 99th percentile
    67 of 8009
    Sector 97th percentile
    18 of 687 in Healthcare
    Industry 97th percentile
    5 of 248 in Biotechnology

    BIIB R&D Expense Quarterly Range, Past 5 Years

    Minimum 45.87M Dec 2010
    Maximum 524.05M Sep 2010
    Average 309.22M